Nuvation Bio announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access. “We are thrilled to welcome Colleen as Nuvation Bio’s first Chief Commercial Officer. She is an accomplished leader who has developed innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines. Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI(R),” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “Colleen joins us at an exciting moment, as we work toward transforming into a late-stage global oncology company with the potential to become commercial-stage by the end of 2025, all while advancing multiple novel therapies for patients with the most difficult-to-treat cancers.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
- Nuvation Bio upgraded to Buy from Hold at Jefferies
- Nuvation Bio upgraded to Buy from Neutral at BTIG
- Nuvation Bio Enhances Capabilities with AnHeart Merger Deal
- Nuvation Bio to acquire AnHeart Therapeutics in all-stock transaction